Phase I-II study of combination chemotherapy with Irinotecan and Gemcitabine for clear cell or mucinous ovarian cancer

Phase 1

• Conditions: Clear cell or mucinous ovarian cancer

• Registration Number: JPRN-UMIN000005952
• Lead Sponsor: Osaka university, faculty of medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-07-08
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who have a history of severe hypersensitivity to drug. 2)Patients with interstitial pneumonia. 3)Patients who have mmasive ascites and/or pleural effusion. 4)Patients who have severe infectious diseases. 5)Patients with other malignant disease. 6)Women at pregnant state or possibly pregnant women. 7)Patients with mental diseases. 8)Patients with symptomatic brain metastasis. 9)Patients with severe coronary disease. 10) Patients with uncontrollable diabetic disease. 11)Patients with watery diarrhea. 12)Patients with severe ileus. 13)Patients with intestinal bleeding. 14)Patients with positeve HBs antigen. 15)Patients with severe medical complications. 16)Patients with systematic edema. 17)Patients who are considered inappropriate for this study by the doctor.

Study & Design

• Study Type: Interventional
• Study Design: Not specified